(:MNTA)

Oct 01, 2020 08:44 am ET
Momenta Pharmaceuticals Announces Completion of Proposed Sale to Johnson & Johnson
Momenta Pharmaceuticals, Inc. (NASDAQ: MNTA, “Momenta” or the “Company”), a biotechnology company focused on discovering and developing novel biologic therapeutics to treat rare immune-mediated diseases, today announced the successful completion of...
Sep 21, 2020 10:00 am ET
MERGER ALERT – SBPH, IMMU, and MNTA: Levi & Korsinsky, LLP Reminds Investors of Investigations Concerning the Mergers of these Companies
NEW YORK, NY / ACCESSWIRE / September 21, 2020 / The following statement is being issued by Levi & Korsinsky, LLP:
Sep 17, 2020 03:00 pm ET
MERGER ALERT – ONK and MNTA: Levi & Korsinsky, LLP Reminds Investors of Investigations Concerning the Mergers of these Companies
NEW YORK, NY / ACCESSWIRE / September 17, 2020 / The following statement is being issued by Levi & Korsinsky, LLP:
Sep 16, 2020 02:31 pm ET
Bragar Eagel & Squire, P.C. Reminds Investors that it is Investigating the Boards of Directors of Rosetta Stone, Momenta, Jernigan, and Varian on behalf of Stockholders and Encourages Investors to Con
Bragar Eagel & Squire, P.C. reminds investors that it is investigating potential claims on behalf of stockholders of Rosetta Stone Inc. (NYSE: RST), Momenta Pharmaceuticals, Inc. (NASDAQ: MNTA), Jernigan Capital, Inc. (NYSE: JCAP), and Varian...
Sep 15, 2020 08:00 am ET
Momenta Pharmaceuticals Announces Expiration of Hart-Scott-Rodino Waiting Period in Connection with Proposed Sale to Johnson & Johnson
Momenta Pharmaceuticals, Inc. (NASDAQ: MNTA, “Momenta” or the “Company”), a biotechnology company focused on discovering and developing novel biologic therapeutics to treat rare immune-mediated diseases, today announced the expiration of the...
Sep 03, 2020 12:52 pm ET
Moore Kuehn Encourages MNTA, AIMT, ONDK, and OTEL Investors to Contact Law Firm
Moore Kuehn, PLLC, a securities litigation law firm located on Wall Street in downtown New York City, is investigating potential claims concerning whether the following proposed mergers are fair to shareholders.  Moore Kuehn may ultimately seek...
Sep 01, 2020 07:17 pm ET
Lifshitz Law Firm, P.C. Announces Investigation of Cancer Genetics, Inc., Momenta Pharmaceuticals, Inc., Principia Biopharma Inc., and Yintech Investment Holdings Limited
Cancer Genetics, Inc. (NASDAQ: CGIX) Lifshitz Law Firm, P.C. announces investigation into possible breach of fiduciary duties in connection with the merger of CGIX with StemoniX, Inc. If you are a JCAP investor, and would like additional...
Aug 27, 2020 12:45 pm ET
MERGER ALERT – CGIX, PRNB, and MNTA: Levi & Korsinsky, LLP Reminds Investors of Investigations Concerning the Mergers of these Companies
NEW YORK, NY / ACCESSWIRE / August 27, 2020 / The following statement is being issued by Levi & Korsinsky, LLP:
Aug 24, 2020 06:25 pm ET
MERGER ALERT - MNTA, MR, and PFNX: Levi & Korsinsky, LLP Reminds Investors of Investigations Concerning the Mergers of these Companies
NEW YORK, NY / ACCESSWIRE / August 24, 2020 / The following statement is being issued by Levi & Korsinsky, LLP:
Aug 20, 2020 11:42 am ET
MOMENTA INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Momenta Pharmaceuticals, Inc. - MNTA
Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Momenta Pharmaceuticals, Inc. (NasdaqGS: MNTA) to Johnson & Johnson (NYSE: JNJ). Under the terms of the proposed transaction, shareholders of Momenta will receive only $52.50 in cash for each share of Momenta that they own. KSF is seeking to determine whether this consideration and the process that led to it are adequate, or whether the consideration undervalues the Company.
Aug 19, 2020 12:59 pm ET
MOMENTA PHARMACEUTICALS, INC. SHAREHOLDER ALERT: Rigrodsky & Long, P.A. Announces Investigation of Buyout
Rigrodsky & Long, P.A. announces that it is investigating Momenta Pharmaceuticals, Inc. (“Momenta”) (NASDAQ GS: MNTA) regarding possible breaches of fiduciary duties and other violations of law related to Momenta’s agreement to be acquired by...
Aug 19, 2020 12:52 pm ET
MOMENTA ALERT: Bragar Eagel & Squire, P.C. Investigates Sale of MNTA and Encourages Investors to Contact the Firm
Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, has launched an investigation into whether the board members of Momenta Pharmaceuticals, Inc. (NASDAQ: MNTA) breached their fiduciary duties or violated the federal securities laws in connection with the company’s acquisition by Johnson & Johnson (NYSE: JNJ) (“JNJ”).
Aug 19, 2020 06:35 am ET
Momenta Enters Definitive Agreement with Johnson & Johnson
Momenta Pharmaceuticals, Inc. (Nasdaq: MNTA, “Momenta” or the “Company”), a biotechnology company focused on discovering and developing novel biologic therapeutics to treat rare immune-mediated diseases announced today that it has entered into a...
Aug 10, 2020 07:00 am ET
Momenta Pharmaceuticals Reports Second Quarter 2020 Financial and Operating Results
Momenta Pharmaceuticals, Inc. (Nasdaq: MNTA), a biotechnology company focused on discovering and developing novel biologic therapeutics to treat rare immune-mediated diseases, today reported its financial results for the second quarter ended June...
Aug 03, 2020 07:30 am ET
Momenta Pharmaceuticals Announces Date of Second Quarter 2020 Financial Results Conference Call and Webcast
Momenta Pharmaceuticals, Inc. (NASDAQ: MNTA), a biotechnology company focused on discovering and developing novel biologic therapeutics to treat rare immune-mediated diseases, today announced that it will release its financial results for the...
Jul 28, 2020 09:31 am ET
Thinking about trading options or stock in Momenta Pharmaceuticals, Xerox, Canopy Growth Corp, Apple, or Plug Power?
NEW YORK, July 28, 2020 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for MNTA, XRX, CGC, AAPL, and PLUG.
Jul 28, 2020 07:15 am ET
Momenta Pharmaceuticals Announces FDA Rare Pediatric Disease Designation for Nipocalimab in HDFN
Momenta Pharmaceuticals, Inc. (NASDAQ: MNTA) today announced that its novel drug candidate, nipocalimab, has received rare pediatric disease designation from the U.S. Food and Drug Administration (FDA) for the prevention of hemolytic disease of the...
Jun 15, 2020 07:05 am ET
Momenta Pharmaceuticals Announces Positive Topline Data from Interim Analysis of Phase 2 Vivacity-MG Study of Nipocalimab (M281) in Generalized Myasthenia Gravis (gMG)
Nipocalimab induced a rapid and durable response in the myasthenia gravis activities of daily living score (MG-ADL) at all doses - - Nipocalimab was well tolerated, with no adverse events leading to discontinuation -                    –...
May 07, 2020 07:00 am ET
Momenta Pharmaceuticals Reports First Quarter 2020 Financial and Operating Results
Momenta Pharmaceuticals, Inc. (Nasdaq: MNTA), a biotechnology company focused on discovering and developing novel biologic therapeutics to treat rare immune-mediated diseases, today reported its financial results for the first quarter ended March...
Apr 23, 2020 08:00 am ET
Momenta Pharmaceuticals Announces Date of First Quarter 2020 Financial Results Conference Call and Webcast
Momenta Pharmaceuticals, Inc. (NASDAQ: MNTA), a biotechnology company focused on discovering and developing novel biologic therapeutics to treat rare immune-mediated diseases, today announced that it will release its financial results for the first...
Apr 02, 2020 07:30 am ET
Momenta Provides Corporate Update Amid COVID-19 Pandemic
Momenta Pharmaceuticals, Inc. (NASDAQ: MNTA), a biotechnology company focused on discovering and developing novel biologic therapeutics to treat rare immune-mediated diseases, today provided an update on the Company’s clinical trial activities and...
Feb 26, 2020 07:00 am ET
Momenta Pharmaceuticals Reports Fourth Quarter and Full Year 2019 Financial Results
Momenta Pharmaceuticals, Inc. (Nasdaq: MNTA), a biotechnology company focused on discovering and developing novel biologic therapeutics to treat rare immune-mediated diseases, today reported its financial results for the fourth quarter and full...
Feb 19, 2020 08:00 am ET
Momenta Pharmaceuticals to Webcast Presentation at the Cowen 40th Annual Health Care Conference
Momenta Pharmaceuticals, Inc. (NASDAQ: MNTA), a biotechnology company focused on discovering and developing novel biologic therapeutics to treat rare immune-mediated diseases, today announced that it will present at the Cowen 40th Annual Health...
Feb 12, 2020 08:00 am ET
Momenta Pharmaceuticals Announces Date of Fourth Quarter and Year End 2019 Financial Results Conference Call and Webcast
Momenta Pharmaceuticals, Inc. (NASDAQ: MNTA), a biotechnology company focused on discovering and developing novel biologic therapeutics to treat rare immune-mediated diseases, today announced that it will release its financial results for the...
Jan 13, 2020 07:10 am ET
Momenta Provides Year-End 2019 Update and 2020 Outlook
Momenta Pharmaceuticals, Inc. (NASDAQ: MNTA), a biotechnology company focused on discovering and developing novel biologic therapeutics to treat rare immune-mediated diseases, today provided a 2019 year-end corporate update and key anticipated...
Jan 03, 2020 08:05 am ET
Momenta Pharmaceuticals Announces CFO Transition
Momenta Pharmaceuticals, Inc. (Nasdaq: MNTA) (“Momenta” or the “Company”), a biotechnology company focused on discovering and developing novel biologic therapeutics to treat rare immune-mediated diseases, today announced that it is consolidating...
Dec 24, 2019 08:00 am ET
Momenta Pharmaceuticals to Webcast Presentation at the 38th Annual J.P. Morgan Healthcare Conference
Momenta Pharmaceuticals, Inc. (NASDAQ: MNTA), today announced that Craig Wheeler, President and CEO, will present at the 38th Annual J.P. Morgan Healthcare Conference. The presentation is scheduled for Tuesday, January 14, 2020 at 3:00 p.m. PT...
Dec 13, 2019 08:00 am ET
Momenta Pharmaceuticals Appoints Dr. Jane F. Barlow to Board of Directors
Momenta Pharmaceuticals, Inc. (NASDAQ: MNTA) today announced the appointment of Jane F. Barlow, M.D., M.P.H., M.B.A. to its Board of Directors. “Dr. Barlow’s expertise in market access and commercial pricing will be invaluable as we continue to...
Dec 12, 2019 08:00 am ET
Momenta Pharmaceuticals Announces Pricing of Public Offering of Common Stock
Momenta Pharmaceuticals, Inc. (Nasdaq: MNTA) today announced the pricing of its underwritten public offering of 14,516,130 shares of its common stock at the public offering price of $15.50 per share for total gross proceeds to Momenta of...
Dec 10, 2019 04:04 pm ET
Momenta Pharmaceuticals Announces Proposed Public Offering of Common Stock
Momenta Pharmaceuticals, Inc. (Nasdaq: MNTA) today announced that it is commencing an underwritten registered public offering of $200,000,000 of shares of its common stock. Momenta also expects to grant the underwriters of the offering an option to...
Nov 07, 2019 08:00 am ET
Momenta Pharmaceuticals Announces Poster Presentation at the 61st American Society of Hematology Annual Meeting and Exposition
Momenta Pharmaceuticals, Inc. (NASDAQ: MNTA) today announced that Santiago Arroyo, M.D., Ph.D., Chief Medical Officer, will deliver a poster presentation at the upcoming 61st American Society of Hematology (ASH) Annual Meeting and Exposition being...
Nov 06, 2019 08:00 am ET
Momenta Pharmaceuticals to Webcast Presentation at Two Upcoming Investor Conferences
Momenta Pharmaceuticals, Inc. (NASDAQ: MNTA), a biotechnology company focused on discovering and developing novel biologic therapeutics to treat rare immune-mediated diseases, today announced that it will webcast its presentation at two upcoming...
Oct 31, 2019 07:00 am ET
Momenta Pharmaceuticals Reports Third Quarter 2019 Financial and Operating Results
Momenta Pharmaceuticals, Inc. (Nasdaq: MNTA), a biotechnology company focused on discovering and developing novel biologic therapeutics to treat rare immune-mediated diseases, today reported its financial results for the third quarter ended...
Oct 17, 2019 08:00 am ET
Momenta Pharmaceuticals Announces Date of Third Quarter 2019 Financial Results Conference Call and Webcast
Momenta Pharmaceuticals, Inc. (NASDAQ: MNTA), a biotechnology company focused on discovering and developing novel biologic therapeutics to treat rare immune-mediated diseases, today announced that it will release its financial results for the third...
Sep 19, 2019 08:00 am ET
Momenta Pharmaceuticals Appoints Dr. Donna Grogan to Board of Directors
Momenta Pharmaceuticals, Inc. (Nasdaq: MNTA), a biotechnology company focused on discovering and developing novel biologic therapeutics to treat rare immune-mediated diseases, today announced the appointment of Donna Grogan, M.D. to its Board of...
Aug 02, 2019 07:00 am ET
Momenta Pharmaceuticals Reports Second Quarter 2019 Financial and Operating Results
Momenta Pharmaceuticals, Inc. (Nasdaq: MNTA), a biotechnology company focused on discovering and developing novel biologic therapeutics to treat rare immune-mediated diseases, today reported its financial results for the second quarter ended June...
Aug 01, 2019 04:05 pm ET
Momenta Pharmaceuticals Launches Phase 2/3 Trial of M281 for the Treatment of Warm Autoimmune Hemolytic Anemia and is Granted FDA Fast Track Designation
Momenta Pharmaceuticals, Inc. (Nasdaq: MNTA), a biotechnology company focused on discovering and developing novel biologic therapeutics to treat rare immune-mediated diseases, announced the launch of an adaptive Phase 2/3 clinical study for its...
Jul 30, 2019 07:00 am ET
Momenta Pharmaceuticals Announces Fast Track Designation for M281 (nipocalimab) in Hemolytic Disease of the Fetus and Newborn (HDFN)
Momenta Pharmaceuticals, Inc. (Nasdaq: MNTA), a biotechnology company focused on discovering and developing novel biologic therapeutics to treat rare immune-mediated diseases, today announced that the U.S. Food and Drug Administration (FDA) has...
Jul 19, 2019 08:00 am ET
Momenta Pharmaceuticals Announces Date of Second Quarter 2019 Financial Results Conference Call and Webcast
Momenta Pharmaceuticals, Inc. (NASDAQ: MNTA), a biotechnology company focused on discovering and developing novel biologic therapeutics to treat rare immune-mediated diseases, today announced that it will release its financial results for the...
Jun 19, 2019 08:00 am ET
Momenta Pharmaceuticals Announces Settlement Agreement with Amphastar Resolving Enoxaparin Sodium Injection Litigation
Momenta Pharmaceuticals, Inc. (Nasdaq: MNTA), a biotechnology company focused on discovering and developing novel biologic therapeutics to treat rare immune-mediated diseases, today announced that Momenta, Sandoz AG and Amphastar Pharmaceuticals...
Jun 04, 2019 07:30 am ET
Momenta Pharmaceuticals to Webcast Presentation at the Goldman Sachs 40th Annual Global Healthcare Conference
Momenta Pharmaceuticals, Inc. (NASDAQ: MNTA), a biotechnology company focused on discovering and developing novel biologic therapeutics to treat rare immune-mediated diseases, today announced that Craig Wheeler, President and CEO, will present at...
May 09, 2019 08:00 am ET
Momenta Pharmaceuticals to Webcast Presentation at the 2019 Bank of America Merrill Lynch Healthcare Conference
Momenta Pharmaceuticals, Inc. (NASDAQ: MNTA), a biotechnology company focused on discovering and developing novel biologic therapeutics to treat rare immune-mediated diseases, today announced that Craig Wheeler, President and CEO, will present at...
May 02, 2019 07:00 am ET
Momenta Pharmaceuticals Reports First Quarter 2019 Financial and Operating Results
Momenta Pharmaceuticals, Inc. (Nasdaq: MNTA), a biotechnology company focused on discovering and developing novel biologic therapeutics to treat rare immune-mediated diseases, today reported its financial results for the first quarter ended March...
Apr 18, 2019 08:00 am ET
Momenta Pharmaceuticals Announces Date of First Quarter 2019 Financial Results Conference Call and Webcast
Momenta Pharmaceuticals, Inc. (NASDAQ: MNTA), a biotechnology company focused on discovering and developing novel biologic therapeutics to treat rare immune-mediated diseases, today announced that it will release its financial results for the first...
Mar 29, 2019 07:35 am ET
New Research Coverage Highlights American International Group, Fox Factory Holding, Momenta Pharmaceuticals, Mercer International, Endurance International Group, and Addus HomeCare — Consolidated Reve
In new independent research reports released early this morning, Capital Review released its latest key findings for all current investors, traders, and shareholders of American International Group, Inc. (NYSE:AIG), Fox Factory Holding Corp....
Mar 28, 2019 07:00 am ET
Momenta Pharmaceuticals Announces Presentations at the American Association for Cancer Research (AACR) Annual Meeting 2019
Momenta Pharmaceuticals, Inc. (Nasdaq: MNTA), a biotechnology company focused on discovering and developing novel biologic therapeutics to treat rare immune-mediated diseases, today announced the selection of new research for presentation at the...
Mar 21, 2019 08:43 am ET
Momenta Pharmaceuticals Announces Publication of New Data Supporting M281 as First Anti-FcRn Antibody to Inhibit Maternal-Fetal IgG Transfer in the Human Term Placenta  
Momenta Pharmaceuticals, Inc. (Nasdaq: MNTA), a biotechnology company focused on discovering and developing novel biologic therapeutics to treat rare immune-mediated diseases, today announced new preclinical data for M281, its potentially...
Feb 22, 2019 06:30 am ET
Momenta Pharmaceuticals Reports Fourth Quarter and Full Year 2018 Financial Results
CAMBRIDGE, Mass., Feb. 22, 2019 (GLOBE NEWSWIRE) -- Momenta Pharmaceuticals, Inc. (Nasdaq: MNTA), a biotechnology company focused on discovering and developing novel biologic therapeutics to treat rare immune-mediated diseases, today reported...
Feb 08, 2019 08:00 am ET
Momenta Pharmaceuticals Announces Date of Fourth Quarter and Year End 2018 Financial Results Conference Call and Webcast
Momenta Pharmaceuticals, Inc. (NASDAQ: MNTA), a biotechnology company focused on discovering and developing novel biologic therapeutics to treat rare immune-mediated diseases, today announced that it will release its financial results for the...
Feb 07, 2019 08:00 am ET
Momenta Pharmaceuticals Announces Oral Presentation of New Data for M281 at the Society for Maternal-Fetal Medicine 2019 Annual Meeting
Momenta Pharmaceuticals, Inc. (Nasdaq: MNTA), a biotechnology company focused on discovering and developing novel biologic therapeutics to treat rare immune-mediated diseases, today announced the selection of new research for its product candidate,...
Jan 29, 2019 08:00 am ET
Momenta Pharmaceuticals Announces First Subject Dosed in Phase 1/2 Clinical Trial of M254, Hypersialylated Immunoglobulin G
Momenta Pharmaceuticals, Inc. (Nasdaq: MNTA), a biotechnology company focused on discovering and developing novel biologic therapeutics to treat rare immune-mediated diseases, today announced the dosing of the first subject in the Phase 1/2...
Jan 23, 2019 07:55 am ET
New Research Coverage Highlights Lennox International, Momenta Pharmaceuticals, Westlake Chemical Partners LP, Symantec, American Eagle Outfitters, and FTD Companies — Consolidated Revenues, Company G
In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors, traders, and shareholders of Lennox International, Inc. (NYSE:LII), Momenta Pharmaceuticals, Inc....
Jan 02, 2019 08:00 am ET
Momenta Pharmaceuticals to Webcast Presentation at the 37th Annual J.P. Morgan Healthcare Conference
Momenta Pharmaceuticals, Inc. (NASDAQ: MNTA), today announced that Craig Wheeler, President and CEO, will present at the 37th Annual J.P. Morgan Healthcare Conference.  The presentation is scheduled for Wednesday, January 9, 2019 at 10:00 a.m. PT...
Dec 11, 2018 04:05 pm ET
Momenta Pharmaceuticals Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriter’s Option to Purchase Additional Shares
Momenta Pharmaceuticals, Inc. (Nasdaq: MNTA), a biotechnology company with a validated scientific platform focused on discovering and developing novel therapeutics to treat rare, immune-mediated diseases, today announced the closing of its...
Dec 06, 2018 08:13 pm ET
Momenta Pharmaceuticals Announces Pricing of Public Offering of Common Stock
Momenta Pharmaceuticals, Inc. (Nasdaq: MNTA), a biotechnology company with a validated scientific platform focused on discovering and developing novel therapeutics to treat rare, immune-mediated diseases, today announced the pricing of its...
Dec 05, 2018 04:15 pm ET
Momenta Pharmaceuticals Announces Proposed Public Offering of Common Stock
Momenta Pharmaceuticals, Inc. (Nasdaq: MNTA), a biotechnology company with a validated scientific platform focused on discovering and developing novel therapeutics to treat rare, immune-mediated diseases, today announced that it is commencing an...
Dec 03, 2018 04:05 pm ET
Momenta Pharmaceuticals Provides Update on US Regulatory Strategy for M923, Proposed Biosimilar to HUMIRA®
Momenta Pharmaceuticals, Inc. (Nasdaq: MNTA), a biotechnology company with a validated scientific platform focused on discovering and developing novel therapeutics to treat rare, immune-mediated diseases, today announced a revised regulatory...
Nov 27, 2018 07:30 am ET
Factors of Influence in 2018, Key Indicators and Opportunity within Eclipse Resources, DISH Network, Navigant Consulting, TreeHouse Foods, Momenta Pharmaceuticals, and Party City Holdco — New Research
In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Eclipse Resources Corporation (NYSE:ECR), DISH Network Corporation...
Nov 07, 2018 09:45 am ET
Momenta Pharmaceuticals Announces Publication of Phase 1 Study Data for Anti-FcRn Antibody, M281
Momenta Pharmaceuticals, Inc. (Nasdaq: MNTA) today announced the publication of results from its Phase 1 study of M281 in healthy volunteers in the online edition of the peer-reviewed journal Clinical Pharmacology & Therapeutics. The paper,...
Nov 07, 2018 06:00 am ET
Momenta Pharmaceuticals Reports Third Quarter 2018 Financial Results and Provides Corporate Update
Momenta Pharmaceuticals, Inc. (Nasdaq: MNTA) today reported its financial results for the third quarter ended September 30, 2018 and provided a corporate update. “We recently highlighted our pipeline of novel drug candidates for immune-mediated...
Nov 06, 2018 04:45 pm ET
Momenta Pharmaceuticals Announces Global Settlement with AbbVie to Enable Commercialization of M923, a Proposed Biosimilar to HUMIRA® (adalimumab)
Momenta Pharmaceuticals, Inc. (Nasdaq: MNTA) today announced that it has executed agreements with AbbVie Inc., providing license rights for the global launch of M923, Momenta’s proposed biosimilar to HUMIRA. Under the terms of the agreements and...
Nov 06, 2018 08:00 am ET
Momenta Pharmaceuticals to Webcast Presentation at the Stifel 2018 Healthcare Conference
Momenta Pharmaceuticals, Inc. (NASDAQ: MNTA), today announced that it will present at the Stifel 2018 Healthcare Conference. The presentation is scheduled for Tuesday, November 13, 2018 at 10:15 A.M. ET.  A webcast of the presentation will be...
Oct 31, 2018 08:00 am ET
Momenta Pharmaceuticals Announces Date of Third Quarter 2018 Financial Results Conference Call and Webcast
Momenta Pharmaceuticals, Inc. (NASDAQ: MNTA), today announced that it will release its financial results for the third quarter ended September 30, 2018 and provide a corporate update before the U.S. financial markets open on Wednesday, November 7,...
Oct 11, 2018 07:35 am ET
Recent Analysis Shows RadNet, Electro Scientific Industries, Koppers, Momenta Pharmaceuticals, IQVIA, and Columbia Property Trust Market Influences — Renewed Outlook, Key Drivers of Growth
In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of RadNet, Inc. (NASDAQ:RDNT), Electro Scientific Industries, Inc....
Oct 04, 2018 08:00 am ET
Momenta Pharmaceuticals to Host R&D Day on October 11, 2018
Momenta Pharmaceuticals, Inc. (Nasdaq: MNTA)  today announced that it will host a live webcast of its R Day on Thursday, October 11, 2018 beginning at 8:30 am ET. The event is being held in New York, NY. Momenta’s leadership team plans to...
Oct 01, 2018 06:00 am ET
Momenta Pharmaceuticals Completes Strategic Review to Refocus its Operations and Drive Shareholder Value
Momenta Pharmaceuticals, Inc. (Nasdaq: MNTA) today announced the completion of its strategic review aimed at reducing costs of biosimilar development and focusing its resources on its pipeline of novel drug candidates for immune-mediated diseases....
Aug 09, 2018 06:00 am ET
Momenta Pharmaceuticals Reports Second Quarter 2018 Financial Results and Provides Corporate Update
Momenta Pharmaceuticals, Inc. (Nasdaq:MNTA) today reported its financial results for the second quarter ended June 30, 2018 and provided a corporate update. “The strategic review of our business announced earlier this year is progressing and we...
Aug 06, 2018 07:50 am ET
Recent Analysis Shows Regis, Graco, Columbia Sportswear, Momenta Pharmaceuticals, Interface, and Bunge Market Influences — Renewed Outlook, Key Drivers of Growth
In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Regis Corporation (NYSE:RGS), Graco Inc. (NYSE:GGG), Columbia Sportswear...
Aug 02, 2018 08:00 am ET
Momenta Pharmaceuticals Announces Date of Second Quarter 2018 Financial Results Conference Call and Webcast
Momenta Pharmaceuticals, Inc. (NASDAQ: MNTA), today announced that it will release its financial results for the second quarter ended June 30, 2018 and provide a corporate update before the U.S. financial markets open on Thursday, August 9, 2018....
Jun 06, 2018 04:02 pm ET
Momenta Pharmaceuticals to Webcast Presentation at the Goldman Sachs 39th Annual Global Healthcare Conference
Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA), today announced that it will present at the Goldman Sachs 39th Annual Global Healthcare Conference.  The presentation is scheduled for Wednesday, June 13, 2018 at 2:40 P.M. PT/5:40 P.M. ET. A webcast of...
May 17, 2018 04:05 pm ET
Momenta Pharmaceuticals Announces Presentation on M281, an Anti-FcRn Monoclonal Antibody, at 11th International Congress on Autoimmunity
Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA) today announced the upcoming presentation describing the broad potential for anti-FcRn therapeutics and the discovery of M281. The presentation will be part of the 11th International Congress on...
May 10, 2018 08:00 am ET
Momenta Pharmaceuticals to Webcast Presentation at the Bank of America Merrill Lynch Health Care Conference 2018
Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA), a biotechnology company specializing in the characterization and engineering of complex drugs, today announced that it will present at the Bank of America Merrill Lynch Health Care Conference 2018.  The...
May 08, 2018 07:01 am ET
Momenta Pharmaceuticals Reports First Quarter 2018 Financial Results and Provides Corporate Update
Momenta Pharmaceuticals, Inc. (Nasdaq:MNTA) today reported its financial results for the first quarter ended March 31, 2018 and provided a corporate update. “We made important progress in the first quarter of 2018 across our complex generic,...
May 01, 2018 08:00 am ET
Momenta Pharmaceuticals Announces Date of First Quarter 2018 Financial Results Conference Call and Webcast
CAMBRIDGE, Mass., May 01, 2018 (GLOBE NEWSWIRE) -- Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA), today announced that it will release its financial results for the first quarter ended March 31, 2018 and provide a corporate update before the U.S. financial...
Apr 30, 2018 07:55 am ET
Report: Developing Opportunities within Interface, Oxford Industries, CVR Energy, Cubic, Momenta Pharmaceuticals, and RadiSys — Future Expectations, Projections Moving into 2018
NEW YORK, April 30, 2018 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Interface, Inc. (NASDAQ:TILE), Oxford Industries, Inc....
Mar 20, 2018 08:30 am ET
Report: Developing Opportunities within Heico, Global Medical REIT, Acceleron Pharma, Momenta Pharmaceuticals, Silgan, and Weingarten Realty Investors — Future Expectations, Projections Moving into 20
NEW YORK, March 20, 2018 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Heico Corporation (NYSE:HEI-A), Global Medical REIT...
Mar 05, 2018 08:00 am ET
Momenta Pharmaceuticals to Webcast Presentation at Two Upcoming Investor Conferences
CAMBRIDGE, Mass., March 05, 2018 (GLOBE NEWSWIRE) -- Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA), a biotechnology company specializing in the characterization and engineering of complex drugs, today announced that it will webcast its presentation at two upcoming investor conferences.
Feb 21, 2018 08:00 am ET
Feb 21, 2018 07:40 am ET
Momenta Pharmaceuticals, Inc. to Host Earnings Call
NEW YORK, NY / ACCESSWIRE / February 21, 2018 / Momenta Pharmaceuticals, Inc. (NASDAQ: MNTA) will be discussing their earnings results in their Q4 Earnings Call to be held on February 21, 2018 at 10:00 AM Eastern Time.
Feb 13, 2018 01:15 am ET
Momenta Pharmaceuticals Announces FDA Approval and Launch of Glatopa® (glatiramer acetate injection) 40 mg/mL
--Glatopa 40 mg/mL is a fully substitutable, AP-rated generic version of three times-a-week COPAXONE® (glatiramer acetate injection) 40 mg/mL for the treatment of patients with relapsing forms of multiple sclerosis (MS)--
Feb 08, 2018 08:00 am ET
Momenta Pharmaceuticals to Webcast Presentation at the LEERINK Partners 7th Annual Global Healthcare Conference
CAMBRIDGE, Mass., Feb. 08, 2018 (GLOBE NEWSWIRE) -- Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA), a biotechnology company specializing in the characterization and engineering of complex drugs, today announced that it will webcast its presentation at the LEERINK Partners 7th Annual...
Feb 07, 2018 08:00 am ET
Momenta Pharmaceuticals Announces Date of Fourth Quarter and Year End 2017 Financial Results Conference Call and Webcast
CAMBRIDGE, Mass., Feb. 07, 2018 (GLOBE NEWSWIRE) -- Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA), a biotechnology company specializing in the characterization and engineering of complex drugs, will release its financial results for the fourth quarter and year ended December 31,...
Jan 30, 2018 08:00 am ET
Momenta Pharmaceuticals Announces Positive Outcome for Contracted Glatopa® (glatiramer acetate injection) Fill/Finish Manufacturer
-- McPherson, Kansas facility compliance status amended to Voluntary Action Indicated (VAI)-- -- VAI status provides the potential for the near-term FDA approval of Sandoz’s Glatopa 40 mg ANDA--
Jan 17, 2018 07:55 am ET
New Research Coverage Highlights HTG Molecular Diagnostics, Momenta Pharmaceuticals, Black Knight Financial Services, Verint, IBERIABANK, and Sterling Construction — Consolidated Revenues, Company Gro
NEW YORK, Jan. 17, 2018 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of HTG Molecular Diagnostics, Inc. (NASDAQ:HTGM), Momenta...
Jan 08, 2018 05:55 pm ET
INVESTOR ALERT: Levi & Korsinsky, LLP Announces an Investigation Involving the Board of Momenta Pharmaceuticals, Inc.
Levi & Korsinsky announces it has commenced an investigation of Momenta Pharmaceuticals, Inc. (NASDAQ: MNTA). On February 17, 2017, Momenta announced that a contracted Pfizer facility used to manufacture the Company's Glatopa product had received a warning letter from the U.S. Food and Drug Administration. The Company’s Abbreviated New Drug Application (ANDA) for its Glatopa 40 mg product candidate is still under regulatory review, with final approval reliant upon the acceptable resolution of the compliance observations at the Pfizer manufacturi
Jan 03, 2018 04:05 pm ET
Momenta and Mylan Announce Development Strategy for M710, a Proposed Biosimilar to EYLEA® (aflibercept)
Targeting the initiation of a pivotal patient clinical trial in the first half of 2018
Jan 03, 2018 03:05 pm ET
Momenta and Mylan Announce Development Strategy for M710, a Proposed Biosimilar to EYLEA® (aflibercept)
CAMBRIDGE, Mass. and HERTFORDSHIRE, England and PITTSBURGH, Jan. 3, 2018 /PRNewswire/ -- Momenta Pharmaceuticals, Inc. (Nasdaq: MNTA) and Mylan N.V. (NASDAQ, TASE: MYL) today announced the development strategy for M710, a proposed biosimilar to EYLEA® (aflibercept) injection. EYLEA is the market-leading vascular endothelial growth factor (VEGF) inhibitor indicated for the treatment of neovascular (wet) age-related macular degeneration, macular edema following retinal vein occlusion, diabetic macular edema and diabetic retinopathy in patients with diabetic macular edema. The companies plan to
Dec 28, 2017 08:00 am ET
Momenta Pharmaceuticals to Webcast Presentation at the 36th Annual J. P. Morgan Healthcare Conference
CAMBRIDGE, Mass., Dec. 28, 2017 (GLOBE NEWSWIRE) -- Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA), a biotechnology company specializing in the characterization and engineering of complex drugs, today announced that Craig Wheeler, President and CEO, will present at the 36th Annual...
Nov 08, 2017 08:00 am ET
Momenta Pharmaceuticals to Webcast Presentation at the Stifel 2017 Healthcare Conference
CAMBRIDGE, Mass., Nov. 08, 2017 (GLOBE NEWSWIRE) -- Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA), a biotechnology company specializing in the characterization and engineering of complex drugs, today announced that it will webcast its presentation at the Stifel 2017 Healthcare Conference....
Nov 01, 2017 08:05 am ET
Nov 01, 2017 08:00 am ET
Momenta and Mylan Report Initial Results from Phase 1 Clinical Trial for M834, a Proposed Biosimilar of ORENCIA® (abatacept)
CAMBRIDGE, Mass. and HERTFORDSHIRE, United Kingdom and PITTSBURGH, Nov. 01, 2017 (GLOBE NEWSWIRE) -- Momenta Pharmaceuticals, Inc. (Nasdaq:MNTA) and Mylan N.V. (NASDAQ:MYL) (TASE:MYL), today announced that M834, a proposed biosimilar of ORENCIA (abatacept), did not meet its primary pharmacokinetic...
Oct 18, 2017 08:00 am ET
Momenta Pharmaceuticals Announces Date of Third Quarter 2017 Financial Results Conference Call and Webcast
CAMBRIDGE, Mass., Oct. 18, 2017 (GLOBE NEWSWIRE) -- Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA), a biotechnology company specializing in the characterization and engineering of complex drugs, will release its financial results for the third quarter ended September 30, 2017 before the U.S. financial markets open on Wednesday, November 1, 2017.   ...
Oct 02, 2017 04:05 pm ET
Momenta Pharmaceuticals Promotes Ganesh V. Kaundinya as Chief Operating Officer and Chief Scientific Officer
CAMBRIDGE, Mass., Oct. 02, 2017 (GLOBE NEWSWIRE) -- Momenta Pharmaceuticals, Inc. (Nasdaq:MNTA), a biotechnology company specializing in the characterization and engineering of complex drugs, today announced the promotion of Dr. Ganesh Kaundinya to Chief Operating Officer. Dr. Kaundinya, who assumed his new position effective September 25, 2017, will also continue to serve as Chief Scientific Officer and report directly to Craig Wheeler, Momenta’s President and Chief Executive Officer....
Sep 12, 2017 08:30 am ET
Palatin Technologies Announces Appointment of Anthony M. Manning, Ph.D. to Board of Directors
CRANBURY, N.J., Sept. 12, 2017 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE MKT: PTN), a biopharmaceutical company developing targeted, receptor-specific peptide therapeutics for the treatment of diseases with significant unmet medical need and commercial potential, announced today that Anthony M. Manning, Ph.D. was appointed to Palatin's Board of Directors on September 7, 2017.  Dr. Manning currently serves as the Senior Vice President of Research at Momenta Pharmaceuticals, Inc. (NASDAQ: MNTA), Cambridge, MA.
Jul 21, 2017 02:16 pm ET
Momenta Pharmaceuticals Announces Jury Verdict in Enoxaparin Sodium Injection Patent Litigation Against Amphastar
CAMBRIDGE, Mass., July 21, 2017 (GLOBE NEWSWIRE) -- Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA) today announced that the jury in the District Court for the District of Massachusetts in Boston has issued its verdict finding that the Company’s U.S. Patent No. 7,575,886, covering methods for the manufacturing of generic LOVENOX® (Enoxaparin Sodium Injection), was infringed, but invalid and unenforceable....
Jun 07, 2017 08:00 am ET
Momenta Pharmaceuticals to Webcast Presentation at the Goldman Sachs 38th Annual Global Healthcare Conference
CAMBRIDGE, Mass., June 07, 2017 (GLOBE NEWSWIRE) -- Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA), a biotechnology company specializing in the characterization and engineering of complex drugs, today announced that it will provide a corporate overview, including an update on the timing of regulatory submissions for marketing approval for M923, its biosimilar HUMIRA® (adalimumab) candidate, at the Goldman Sachs 38th Annual Global Healthcare Conference. The presentation is scheduled for Wednesday, June 14th at 11:20 a.m. PT/2:20 p.m. ET. ...
May 10, 2017 04:05 pm ET
UPDATE -- Momenta Pharmaceuticals to Webcast Presentation at Two Upcoming Investor Conferences
CAMBRIDGE, Mass., May 10, 2017 (GLOBE NEWSWIRE) -- Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA), a biotechnology company specializing in the characterization and engineering of complex drugs, today announced that it will webcast its presentation at two upcoming investor conferences....
May 10, 2017 08:00 am ET
Momenta Pharmaceuticals to Webcast Presentation at Two Upcoming Investor Conferences
CAMBRIDGE, Mass., May 10, 2017 (GLOBE NEWSWIRE) -- Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA), a biotechnology company specializing in the characterization and engineering of complex drugs, today announced that it will webcast its presentation at two upcoming investor conferences....
Apr 18, 2017 08:00 am ET
Momenta Pharmaceuticals Announces Date of First Quarter 2017 Financial Results Conference Call and Webcast
CAMBRIDGE, Mass., April 18, 2017 (GLOBE NEWSWIRE) -- Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA), a biotechnology company specializing in the characterization and engineering of complex drugs, will release its financial results for the first quarter ended March 31, 2017 before the U.S. financial markets open on Tuesday, May 2, 2017.   ...
Mar 07, 2017 11:09 am ET
INVESTOR ALERT: Levi & Korsinsky, LLP Announces an Investigation Involving the Board of Momenta Pharmaceuticals, Inc. -- MNTA
NEW YORK, March 7, 2017 /PRNewswire/ -- Levi & Korsinsky announces it has commenced an investigation of Momenta Pharmaceuticals, Inc. (NASDAQ: MNTA). On February 17, 2017, Momenta announced that a contracted Pfizer facility used to manufacture the Company's Glatopa product had received a warning letter from the U.S. Food and Drug Administration. The Company's Abbreviated New Drug Application (ANDA) for its Glatopa 40 mg product candidate is still under regulatory review, with final approval reliant upon the acceptable resolution of the compliance observations at the Pfizer manufacturing
Feb 28, 2017 08:00 am ET
Momenta Pharmaceuticals to Webcast Presentation at the Cowen and Company 37th Annual Health Care Conference
CAMBRIDGE, Mass., Feb. 28, 2017 (GLOBE NEWSWIRE) -- Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA), a biotechnology company specializing in the characterization and engineering of complex drugs, today announced that it will present at the Cowen and Company 37th Annual Health Care Conference. The presentation is scheduled for Tuesday, March 7th at 10:40 a.m. ET. ...
Feb 22, 2017 10:10 am ET
SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Momenta Pharmaceuticals, Inc. (MNTA)
NEW YORK, Feb. 22, 2017 /PRNewswire/ -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Momenta Pharmaceuticals, Inc. ("Momenta" or the "Company") (NASDAQ: MNTA). Such investors are encouraged to obtain additional information and assist the investigation by visiting the firm's site: www.bgandg.com/mnta.
Feb 21, 2017 01:37 pm ET
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Momenta Pharmaceuticals, Inc. - MNTA
NEW YORK, Feb. 21, 2017 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Momenta Pharmaceuticals, Inc. ("Momenta" or the "Company") (NASDAQ: MNTA).   Such investors are advised to contact Robert S. Willoughby at [email protected] or 888-476-6529, ext. 9980.
Feb 21, 2017 07:00 am ET
Momenta Pharmaceuticals Reports Fourth Quarter and Year End 2016 Financial Results
CAMBRIDGE, Mass., Feb. 21, 2017 (GLOBE NEWSWIRE) -- Momenta Pharmaceuticals, Inc. (Nasdaq:MNTA) today reported its financial results for the fourth quarter and year ended December 31, 2016....
Feb 17, 2017 06:05 pm ET
Momenta Pharmaceuticals Announces Time Change for Fourth Quarter and Year End 2016 Financial Results Conference Call and Webcast
CAMBRIDGE, Mass., Feb. 17, 2017 (GLOBE NEWSWIRE) -- Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA), announced today that is has changed the time for its fourth quarter and year end 2016 earnings conference call and webcast. Momenta will now host its conference call and webcast at 8:00 a.m. ET on Tuesday, February 21, 2017.   ...
Feb 17, 2017 06:00 pm ET
Momenta Pharmaceuticals Announces FDA Warning Letter to Contracted Glatopa® (glatiramer acetate injection) Fill/Finish Manufacturer
 Approval of the Glatopa 40 mg ANDA will be dependent on resolution of Pfizer facility compliance issues...
Feb 07, 2017 08:00 am ET
Momenta Pharmaceuticals Announces Date of Fourth Quarter and Year End 2016 Financial Results Conference Call and Webcast
CAMBRIDGE, Mass., Feb. 07, 2017 (GLOBE NEWSWIRE) -- Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA), a biotechnology company specializing in the characterization and engineering of complex drugs, will release its financial results for the fourth quarter and year ended December 31, 2016 before the U.S. financial markets open on Tuesday, February 21, 2017.   ...
Feb 01, 2017 08:00 am ET
Momenta Pharmaceuticals to Webcast Presentation at the Leerink Partners 6th Annual Global Healthcare Conference
CAMBRIDGE, Mass., Feb. 01, 2017 (GLOBE NEWSWIRE) -- Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA), a biotechnology company specializing in the characterization and engineering of complex drugs, today announced that it will present at the Leerink Partners 6th Annual Global Healthcare Conference. The presentation is scheduled for Wednesday, February 15th at 10:30 a.m. ET....
Jan 05, 2017 04:01 pm ET
Momenta and CSL Announce Collaboration and License Agreement to Develop Fc Multimer Programs, Including M230, a Selective Immunomodulator of Fc Receptors
--Momenta to receive $50 million upfront license fee and up to $550 million in potential milestone payments from CSL--...
Nov 02, 2016 09:00 am ET
Momenta and Mylan Initiate Phase 1 Clinical Trial for M834, a Proposed Biosimilar of ORENCIA® (abatacept)
CAMBRIDGE, Mass. and HERTFORDSHIRE, England and PITTSBURGH, Nov. 2, 2016 /PRNewswire/ -- Momenta Pharmaceuticals, Inc. (Nasdaq: MNTA) and Mylan N.V. (NASDAQ, TASE: MYL), today announced that dosing has begun in a Phase 1 study to compare the pharmacokinetics, safety and immunogenicity of M834, a proposed biosimilar of ORENCIA (abatacept), to US- and EU-sourced ORENCIA in normal healthy volunteers. Under the Momenta-Mylan collaboration agreement, Momenta has achieved the milestone necessary to earn a $25 million payment from Mylan.
Nov 02, 2016 08:00 am ET
Momenta and Mylan Initiate Phase 1 Clinical Trial for M834, a Proposed Biosimilar of ORENCIA® (abatacept)
CAMBRIDGE, Mass., HERTFORDSHIRE, England and PITTSBURGH, Nov. 02, 2016 (GLOBE NEWSWIRE) -- Momenta Pharmaceuticals, Inc. (Nasdaq:MNTA) and Mylan N.V. (NASDAQ:MYL) (TASE:MYL), today announced that dosing has begun in a Phase 1 study to compare the pharmacokinetics, safety and immunogenicity of M834, a proposed biosimilar of ORENCIA (abatacept), to US- and EU-sourced ORENCIA in normal healthy volunteers. Under the Momenta-Mylan collaboration agreement, Momenta has achieved the milestone necessary to earn a $25 million payment from Mylan....
Nov 02, 2016 08:00 am ET
Momenta Pharmaceuticals Appoints Scott M. Storer as Senior Vice President and Chief Financial Officer
CAMBRIDGE, Mass., Nov. 02, 2016 (GLOBE NEWSWIRE) -- Momenta Pharmaceuticals, Inc. (Nasdaq:MNTA), a biotechnology company specializing in the characterization and engineering of complex drugs, today announced the appointment of Scott M. Storer as Senior Vice President and Chief Financial Officer. Mr. Storer is expected to begin at Momenta on November 28, 2016 and will replace Momenta’s current Chief Financial Officer, Rick Shea, who will be retiring. Mr. Storer will report directly to Craig Wheeler, Momenta’s President and Chief Executive Officer, and will serve as a member of the Executive...
Nov 02, 2016 08:00 am ET
Momenta Pharmaceuticals Reports Third Quarter 2016 Financial Results
--Company appoints Scott M. Storer as SVP and CFO--...
Oct 31, 2016 08:00 am ET
Momenta Pharmaceuticals to Webcast at Two Upcoming Investor Conferences
CAMBRIDGE, Mass., Oct. 31, 2016 (GLOBE NEWSWIRE) -- Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA), a biotechnology company specializing in the characterization and engineering of complex drugs, today announced that it will webcast its presentation at two upcoming investor conferences....
Oct 20, 2016 08:00 am ET
Momenta Pharmaceuticals Announces Date for Third Quarter 2016 Financial Results Conference Call and Webcast
CAMBRIDGE, Mass., Oct. 20, 2016 (GLOBE NEWSWIRE) -- Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA), a biotechnology company specializing in the characterization and engineering of complex drugs, will release its financial results for the third quarter ended September 30, 2016 before the U.S. financial markets open on Wednesday, November 2, 2016. ...
Sep 27, 2016 08:00 am ET
Momenta Pharmaceuticals to Regain Global Development and Commercialization Rights to M923, a Proposed Biosimilar of HUMIRA® (adalimumab), Through Termination of Collaboration Agreement with Baxalta, N
CAMBRIDGE, Mass., Sept. 27, 2016 (GLOBE NEWSWIRE) -- Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA), a biotechnology company specializing in the characterization and engineering of complex drugs, today announced that Shire has exercised its right to terminate its collaboration agreement with the Company to develop and commercialize M923, a proposed biosimilar of HUMIRA (adalimumab), based on a comprehensive portfolio assessment following the acquisition of Baxalta. Under the terms of the 2011 collaboration agreement, the agreement will terminate twelve months following the notice and Shire wi...
Sep 23, 2016 08:00 am ET
Momenta Pharmaceuticals Appoints Corey N. Fishman to Board of Directors
CAMBRIDGE, Mass., Sept. 23, 2016 (GLOBE NEWSWIRE) -- Momenta Pharmaceuticals, Inc. (Nasdaq:MNTA), a biotechnology company specializing in the characterization and engineering of complex drugs, today announced the appointment of Corey N. Fishman to its Board of Directors effective September 22, 2016. Mr. Fishman currently serves as Chief Executive Officer of Iterum Therapeutics Limited, a clinical-stage pharmaceutical company developing differentiated anti-infectives for combatting multi-drug resistant pathogens....
Aug 31, 2016 04:45 pm ET
Momenta Pharmaceuticals to Webcast Presentation at the 2016 Wells Fargo Healthcare Conference
CAMBRIDGE, Mass., Aug. 31, 2016 (GLOBE NEWSWIRE) -- Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA), a biotechnology company specializing in the characterization and engineering of complex drugs, today announced that it will provide a corporate overview, including an update on the status of the Company’s necuparanib program, at the 2016 Wells Fargo Healthcare Conference in Boston, MA. The presentation is scheduled to begin on Wednesday, September 7th at 1:45 p.m. ET....
Aug 04, 2016 08:00 am ET
Momenta Pharmaceuticals Reports Second Quarter 2016 Financial Results
CAMBRIDGE, Mass., Aug. 04, 2016 (GLOBE NEWSWIRE) -- Momenta Pharmaceuticals, Inc. (Nasdaq:MNTA) today reported its financial results for the second quarter ended June 30, 2016....
Aug 04, 2016 07:50 am ET
Momenta Discontinues Further Accrual of its Phase 2 Trial of Necuparanib in Patients with Pancreatic Cancer Following Planned Interim Futility Analysis
CAMBRIDGE, Mass., Aug. 04, 2016 (GLOBE NEWSWIRE) -- Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA), a biotechnology company specializing in the characterization and engineering of complex drugs, today announced that the Company has discontinued further accrual in its Phase 2 trial evaluating necuparanib in combination with Abraxane® and gemcitabine in patients with advanced metastatic pancreatic cancer....
Jul 21, 2016 08:00 am ET
Momenta Pharmaceuticals Announces Date for Second Quarter 2016 Financial Results Conference Call and Webcast
CAMBRIDGE, Mass., July 21, 2016 (GLOBE NEWSWIRE) -- Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA), a biotechnology company specializing in the characterization and engineering of complex drugs, will release its financial results for the second quarter ended June 30, 2016 before the U.S. financial markets open on Thursday, August 4, 2016. ...
Jun 23, 2016 08:00 am ET
Momenta Pharmaceuticals Appoints Steven C. Gilman, Ph.D. to Board of Directors
CAMBRIDGE, Mass., June 23, 2016 (GLOBE NEWSWIRE) -- Momenta Pharmaceuticals, Inc. (Nasdaq:MNTA), a biotechnology company specializing in the characterization and engineering of complex drugs, today announced the appointment of Steven C. Gilman, Ph.D. to its Board of Directors effective June 22, 2016.  Dr. Gilman was most recently Executive Vice President, Research & Development and Chief Scientific Officer at Cubist Pharmaceuticals, until its acquisition by Merck & Co. in January 2015....
Jun 09, 2016 08:00 am ET
Momenta Pharmaceuticals Initiates Phase 1 Trial of M281, an Anti-FcRn Monoclonal Antibody
CAMBRIDGE, Mass., June 09, 2016 (GLOBE NEWSWIRE) -- Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA), a biotechnology company specializing in the characterization and engineering of complex drugs, today announced the dosing of the first healthy volunteers in a Phase 1 randomized, double-blind, placebo-controlled, ascending-dose cohort study to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of M281, an anti-FcRn monoclonal antibody, for the treatment of autoimmune diseases....
Jun 08, 2016 08:00 am ET
Momenta Pharmaceuticals Announces Data Presentation on M923, a Proposed HUMIRA® (adalimumab) Biosimilar, at EULAR 2016
CAMBRIDGE, Mass., June 08, 2016 (GLOBE NEWSWIRE) -- Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA), a biotechnology company specializing in the characterization and engineering of complex drugs, today announced that key data from a pharmacokinetic/safety study of M923, the Company’s lead biosimilar candidate developed in collaboration with Baxalta, now part of Shire plc, will be presented at the European League Against Rheumatism Annual Congress (EULAR) 2016 Annual Meeting in London....
Jun 04, 2016 09:00 am ET
Momenta Pharmaceuticals Announces Presentation of Final Data from Phase 1 Trial of Necuparanib in Patients with Pancreatic Cancer at ASCO
CAMBRIDGE, Mass., June 04, 2016 (GLOBE NEWSWIRE) -- Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA), a biotechnology company specializing in the characterization and engineering of complex drugs, today presented final data from the Phase 1 trial evaluating necuparanib in combination with nab-paclitaxel (nabP; Abraxane®) and gemcitabine (gem) in patients with advanced metastatic pancreatic cancer (ClinicalTrials.gov Identifier NCT01621243) at the 2016 ASCO Annual Meeting, from 8:00 to 11:30 am CDT (Abstract #4117 / Poster #109) in Chicago, IL....
May 25, 2016 08:00 am ET
Momenta Pharmaceuticals to Webcast Presentation at the Goldman Sachs 37th Annual Global Healthcare Conference
CAMBRIDGE, Mass., May 25, 2016 (GLOBE NEWSWIRE) -- Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA), a biotechnology company specializing in the characterization and engineering of complex drugs, today announced that its presentation at the Goldman Sachs 37th Annual Healthcare Conference will be webcast on Wednesday, June 8th at 8 a.m. PT....
May 19, 2016 08:00 am ET
Momenta Pharmaceuticals Announces Data Presentation on Necuparanib at the 2016 ASCO Annual Meeting
CAMBRIDGE, Mass., May 19, 2016 (GLOBE NEWSWIRE) -- Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA), a biotechnology company specializing in the characterization and engineering of complex drugs, today announced the upcoming presentation of its final results from the Phase 1 study of its drug candidate, necuparanib, in patients with metastatic pancreatic cancer. The poster will be presented at the upcoming American Society of Clinical Oncology (ASCO) 2016 Annual Meeting....

Thank you for visiting InsiderTracking.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you wish to consider using a browser that blocks ads, please log in or subscribe.

Alternatively, if you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). If you are in private browsing mode and do not want to subscribe, please disable tracking protection while visiting our website.

Thank you for using Insider Tracking.